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(Affiliations continued on next page)SUMMARYTo better understand primary and recall T cell responses during coronavirus disease 2019 (COVID-19), it is
important to examine unmanipulated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-spe-
cific T cells. By using peptide-human leukocyte antigen (HLA) tetramers for direct ex vivo analysis, we char-
acterized CD8+ T cells specific for SARS-CoV-2 epitopes in COVID-19 patients and unexposed individuals.
Unlike CD8+ T cells directed toward subdominant epitopes (B7/N257, A2/S269, and A24/S1,208) CD8+ T cells
specific for the immunodominant B7/N105 epitope were detected at high frequencies in pre-pandemic sam-
ples and at increased frequencies during acute COVID-19 and convalescence. SARS-CoV-2-specific CD8+
T cells in pre-pandemic samples from children, adults, and elderly individuals predominantly displayed a
naive phenotype, indicating a lack of previous cross-reactive exposures. T cell receptor (TCR) analyses re-
vealed diverse TCRab repertoires and promiscuous ab-TCR pairing within B7/N105+CD8+ T cells. Our study
demonstrates high naive precursor frequency and TCRab diversity within immunodominant B7/N105-specific
CD8+ T cells and provides insight into SARS-CoV-2-specific T cell origins and subsequent responses.INTRODUCTION
As global research efforts are moving at record speed to
develop and evaluate severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) vaccines, concurrent efforts are1066 Immunity 54, 1066–1082, May 11, 2021 ª 2021 Elsevier Inc.needed to provide an understanding of the optimal immune re-
sponses in coronavirus disease 2019 (COVID-19), thus enabling
the rational design of long-lasting and broadly protective vac-
cines and immunotherapies. Virus-specific CD8+ T cells can
greatly ameliorate recovery from respiratory diseases such as
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Articleavian influenza, SARS, and Middle East respiratory syndrome
(MERS) (Channappanavar et al., 2014; Wang et al., 2015;
Wang et al., 2018; Zhao et al., 2017) and persist long-term as
cross-reactive memory pools (Koutsakos et al., 2019). There-
fore, understanding human epitope-specific CD8+ T cell re-
sponses to SARS-CoV-2 directly ex vivo is needed to better
define the role of CD8+ T cells in primary SARS-CoV-2 infec-
tion, long-term memory persistence, and their subsequent
recall after re-infection and/or vaccination.
SARS-CoV-2-specific CD8+ T cells can be elicited during pri-
mary COVID-19 and survive into short-term convalescence (Dan
et al., 2021). Activated CD8+ T cells, displaying a broad range of
cytotoxic molecules, appear in patients’ blood prior to recovery
(Koutsakos et al., 2021; Thevarajan et al., 2020), suggesting
involvement of CD8+ T cells in the resolution of COVID-19. Acti-
vated T cells directed toward spike (S), membrane (M), nucleo-
capsid (N) and other open reading frames can be detected in
70% of acute and convalescent COVID-19 patients by utilizing
human leukocyte antigen (HLA) class I and II predicted peptide
‘‘megapools’’ to stimulate peripheral blood mononuclear cells
(PBMCs) (Grifoni et al., 2020; Weiskopf et al., 2020). Stimulation
of PBMCs from COVID-19 patients with SARS-CoV-2 overlap-
ping peptides also leads to interferon (IFN)-g production and
clonal expansion of CD8+ T cells in vitro. Thus, both ex vivo
and in vitro studies indicate that CD8+ T cells get activated during
primary SARS-CoV-2 infection.
SARS-CoV-2 CD8+ T cell epitopes (peptides + major histo-
compatibility complex [MHC]-I) are identified for dominant
HLA class I alleles, including HLA-A*01:01, A*02:01, A*03:01,
A*11:01, HLA-B*07:02, B*27:05, B*40:01, and B*44:03, by us-
ing both peptide stimulations and peptide-MHC class I tetra-
mers (Ferretti et al., 2020; Habel et al., 2020; Peng et al., 2020;
Schulien et al., 2021). Identification of SARS-CoV-2 CD8+
T cell epitopes allows accurate determination of the magni-
tude and phenotype of SARS-CoV-2-specific CD8+ T cells
directly ex vivo in COVID-19 patients and in pre-pandemic
PBMCs. It also allows us to precisely define the persistenceof long-term memory CD8+ T cells and their recall after
SARS-CoV-2 re-infection and/or vaccination. Ex vivo fre-
quencies of SARS-CoV-2-specific CD8+ T cells appear to be
present mainly in the range of 1 3 105 to 5 3 105 in the
CD8+ T cell population, which is 2- to 10-fold lower than
the frequency of long-term memory CD8+ T cells specific for
influenza or Epstein-Barr virus (EBV). HLA-A*02:01-restricted
SARS-CoV-2 epitopes appear to exhibit the lowest frequency
of 1 3 105 in the CD8+ T cell population (Habel et al., 2020;
Peng et al., 2020). Direct ex vivo phenotypic analysis of A2/
S269+CD8+ T cells from COVID-19 convalescent individuals re-
vealed that A2/S269+CD8+ T cells were suboptimally stimu-
lated and composed of naive, stem cell memory, and central
memory T cells rather than effector memory populations. In
contrast, the HLA-B*07:02-restricted N105-113 epitope (B7/
N105) appears to be the most dominant SARS-CoV-2 CD8+
T cell specificity known to date (Ferretti et al., 2020; Peng
et al., 2020; Schulien et al., 2021), applicable to 1 in 12 people
globally (Gonzalez-Galarza et al., 2020). The question re-
mains, however, whether these immunodominant B7/
N105+CD8+ T cell responses arise from pre-existing memory
pools established after infection with a cross-reactive sea-
sonal human coronavirus or other pathogens, or whether
they represent a high frequency of naive pools found across
HLA-B*07:02-expressing individuals.
To provide an in-depth understanding of CD8+ T cell re-
sponses directed at the immunodominant B7/N105 epitope,
we performed direct ex vivo analyses in PBMCs from
COVID-19 patients as well as in pre-pandemic PBMCs, ton-
sils, lungs, and spleens. With ex vivo tetramer enrichment, sin-
gle-cell reverse transcriptase (RT)-PCR, and in vitro IFN-g/tu-
mor necrosis factor (TNF) intracellular cytokine secretion (ICS)
assay, we determined the magnitude, naive/effector/memory
phenotype, and molecular T cell receptor (TCR)ab signatures.
Overall, we assessed CD8+ T cells directed at 4 SARS-CoV-2
epitopes: B7/N105, B7/N257, A2/S269, and A24/S1208. In
contrast to the 3 subdominant SARS-CoV-2-specific CD8+Immunity 54, 1066–1082, May 11, 2021 1067
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numerically immunodominant by 4.89- to 38.03-fold in both
COVID-19 patients and pre-pandemic donors. Tetramer-spe-
cific CD8+ T cell populations directed at all 4 SARS-CoV-2
epitopes were predominantly of a naive phenotype in 22 of
the 27 pre-pandemic donors. Together with the TCR data,
the findings support our conclusion that high precursor fre-
quency and promiscuity in ab TCR pairing could underpin
CD8+ T cell responses to an immunodominant SARS-CoV-2
nucleocapsid epitope.
RESULTS
COVID-19 patient cohort and pre-pandemic controls
We recruited a total of 21 COVID-19 subjects, including 8 acute
hospitalized patients and 13 convalescent COVID-19 patients
(Figure 1A; Table S1). Of the 8 patients hospitalized, 1 ICU and
3 ward patients required oxygen support. Ten of the convales-
cents were community SARS-CoV-2 infections. All COVID-19
patients seroconverted for SARS-CoV-2 antibodies. The median
age of COVID-19 patients was 54 years, and 33% of patients
were females. As controls, we analyzed pre-pandemic PBMC
and tonsil samples from 31 subjects across 3 age groups: 4 chil-
dren (median age 6 years, range 3–15), 20 adults (median age 46
years, range 24–63) and 7 elderly (median age 72 years, range
65–76), 37.6% were females. Additionally, we tested pre-exist-
ing B7/CD8+ T cell populations in lung and spleen tissues from
9 HLA-B7 individuals (median age 46 years, range 22–63).
Within this study, a traveler cohort included 3 male SARS-
CoV-2 cases (a 19-year-old CA3 index case with moderate
COVID-19, 1 21-year-old CA2 individual with mild symptoms,
and 1 24-year-old CA1 individual who remained asymptomatic;
Table S1). Four asymptomatic suspected cases (SU1, SU2,
SU3, SU4; all 20 years old) were also investigated. All were re-
turned travelers. Receptor binding domain (RBD) and spike immu-
noglobulin (Ig)G antibody levels were significantly (p < 0.05) higher
in cases (log10 median titer 3.195 RBD IgG; 3.237 spike IgG) than
in suspected cases (log10median titer 1.762RBD IgG; 1.994 spike
IgG) and in healthy unexposed individuals (log10median titer 2.024
RBD IgG; 2.239 spike IgG) (Figure S1A). IgM titers in COVID-19
cases were significantly elevated in comparison with those found
in healthy unexposed individuals (Figure S1A). RBD- and spike-
reactive B cell responses were concordant with the antibody titers
and showed significantly increased frequencies of RBD- and
spike-specific B cells in COVID-19 cases when compared to the
suspected cases (Figures S1B–S1D). Minimal immune cell activa-Figure 1. CD4+ and CD8+ T cell responses to SARS-CoV-2 overlappin
peptides
(A) Overview of cohort and samples collected.
(B) CD4+ and CD8+ T cell responses to SARS-CoV-2 S, N, andM peptide pools in
cell sorting (FACS) plots showing IFN-g and TNF staining of CD4+ or CD8+ T cell p
IFN-g+, TNF+, MIP-1b+, or CD107a+ within the CD4+ or CD8+ T cells, with backg
suspected cases (n = 4); data are shown as mean with SD. Statistical significanc
(C) FACS plots showing IFN-g staining of CD4+ or CD8+ T cell populations from C
the number of IFN-g+ cells are shown. Paired frequencies of IFN-g+CD4+ and CD
(D) FACS plots of CD8+ IFN-g/TNF staining after stimulation with individual N-de
showing CD8+ T cell staining with B7/SARS-CoV-2 tetramers (B7/N66, B7/N105, B
are shown.
See also Table S1 and Figure S3.tion across a broad range of cell populations (CD56+ NK cells,
CD3+ gd T cells, CD8+ T cells, CD4+ T cells, antibody-secreting
cells [ASCs], T follicular helper cells [Tfhs], and monocytes), low
granzyme/perforin levels within CD8+ and CD4+ T cells, and
normal inflammatory milieu (Figure S2) verified lack of acute
COVID-19 in the traveler cohort.
CD4+ and CD8+ T cell responses react to SARS-CoV-2
overlapping peptide pools
Probing SARS-CoV-2-specific CD4+ andCD8+ T cells in the trav-
eler cohort was performed by using overlapping SARS-CoV-2
peptide pools spanning the entire N and M proteins and the
immunogenic regions of S protein, followed by an ICS assay (Fig-
ure 1B). PBMCs were stimulated with 1 peptide pool, expanded
for 10 days before the analysis of SARS-CoV-2-reactive T cells
by ICS for intracellular IFN-g, TNF, MIP-1b, and CD107a (Fig-
ure 1B; Figure S3A). In agreement with the antibody and B cell
data, SARS-CoV-2-reactive CD4+ and CD8+ T cells were de-
tected in COVID-19 cases but not in the suspected cases, with
CD4+ T cells generally dominating over CD8+ T cell populations,
as previously reported (Habel et al., 2020). No differences were
observed between the responses against S, N, and M proteins
for both CD4+ and CD8+ T cells (Figure 1B, right panel). The
exception was CA2 with highly prominent CD8+ T cell responses
directed toward the N peptide pool (IFN-g production up to
25% of CD8+ T cells), markedly above IFN-g-producing
CD4+ T cells (range 0.24%–1.15%) (Figure 1C). Because CA2
was HLA-B*07:02+ and HLA-A*02:01+ (Table S1), we further
dissected the CD8+ T cell response to 5 previously reported
immunogenic peptides derived from N and restricted by both
HLA-B*07:02 and HLA-A*02:01 (B7/N66, B7/N105, B7/N257, A2/
N219, and A2/N222) (Ferretti et al., 2020; Schulien et al., 2021).
In CA2, immunodominant CD8+ T cell responses were directed
toward B7/N105, whereas subdominant CD8+ T cell responses
were against B7/N257, as shown by both IFN-g production to-
ward those peptides and B7/N105, B7/N257, and B7/N66 tetramer
staining (Figure 1D; Figure S3B).
Immunodominant B7/N105+CD8+ T cells possess a high
precursor frequency
To determine the magnitude of SARS-CoV-2-specific CD8+
T cell populations in 19 COVID-19 patients and 23 pre-pandemic
unexposed individuals expressing HLA-B*07:02, HLA-A*02:01,
and/or HLA-A*24:02, we used tetramer-associated magnetic
enrichment (TAME) directly ex vivo (Nguyen et al., 2017b; Valken-
burg et al., 2016) for the immunodominant B7/N105 andg peptide pools and individual SARS-CoV-2 HLA-B*07:02-restricted
COVID-19 cases and suspected cases. Representative fluorescence-activated
opulations; background staining values are shown in brackets. Frequencies of
round staining subtracted in COVID-19 cases (n = 3, 2 time points each) and
e was determined with Mann-Whitney test.
OVID-19 case CA2 V1 and V2 after stimulation with S, N, and M peptide pools;
8+ T cells for S, N, and M peptide pools (right).
rived SARS-CoV-2 peptides (N66, N105, N257, N219, and N222) and FACS plots
7/N257) on expanded cells. Frequency of IFN-g
+CD8+ or tetramer+CD8+ T cells
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S1208 (Ferretti et al., 2020). After validating tetramers in pep-
tide-expanded T cell lines (as shown in Figure 1D), further
ex vivo tetramer validation experiments were performed with
direct ex vivo dual-tetramer staining of the immunodominant
B7/N105 tetramers conjugated to phycoerythrin (PE) and allophy-
cocyanin (APC) fluorophores, as well as dual TAME with B7/N105
tetramer PE and an irrelevant B7/EBV tetramer (EBNA-3379-387,
RPPIFIRRL) conjugated to APC (Figures S4A and S4B).
Following TAME (Figure 2), CD8+ T cells specific for the immuno-
dominant B7/N105 epitope could be readily detected ex vivo in all
COVID-19 patients (Figure 2A; Figure S4C) at a mean frequency
of 6.883 104 (n = 11; Figure 2D), with the B7/N105+CD8+ T cells
being easily detected without enrichment (Figure 2A). B7/N105-
specific CD8+ T cell pools in COVID-19 patients were numerically
immunodominant when compared to 3 subdominant SARS-
CoV-2-specific CD8+ T cell populations directed at B7/N257,
A2/S269, and A24/S1208 epitopes (by 38.03-, 21.54-, and 8.92-
fold respectively; p < 0.05; Figure 2D).
The frequency of B7/N105-specific CD8+ T cells in COVID-19
patients was significantly higher than that in adult (mean 3.00 3
105; p = 0.0017) and elderly (mean 6.76 3 105; p = 0.0023)
pre-pandemic PBMC samples (Figures 2B and 2D), suggesting
clonal expansion after SARS-CoV-2 infection. The values for
pre-pandemic children’s tonsil samples (mean 2.76 3 104) and
elderly PBMCs (mean 6.76 3 105) were variable, with some
elderly individuals showing a decline in the magnitude of B7/
N105-specific CD8+ T cells, most likely reflecting a loss of
tetramer-positive CD8+ T cells with age (Nguyen et al., 2018).
Moreover, the magnitude of the immunodominant B7/N105 in
combined pre-pandemic adult and elderly PBMCs (mean
4.64 3 105) was higher than that for the subdominant B7/N257
(mean 1.52 3 106; p < 0.0001), the previously described A2/
S269 frequencies (Habel et al., 2020) (mean 1.65 3 106; p =
0.0022), and A24/S1208, although not statistically significant
(mean 9.5 3 106; p = 0.2484 Mann-U) (Figure 2D), suggesting
that the immunodominance of B7/N105-specific CD8+ T cell
responses in COVID-19 reflects higher precursor frequencies in
unexposed individuals. Although the frequency of SARS-CoV-2-
specific B7/N105 tetramer-positive CD8+ T cells in children’s
pre-pandemic tonsils (mean 2.76 3 104) appeared higher than
that found in matched PBMCs (mean 2.5 3 105) (Figure 2C),
this difference was not statistically significant (p = 0.125). Analysis
of spleen and lung samples did not show any robust distinct
populations of B7/N105-specific CD8+ T cells in pre-pandemic tis-
sues (Figure S4D). It thus seems that the immunodominant B7/Figure 2. High precursor frequency for immunodominant B7/N105-spec
cific CD8+ T cells
(A and B) B7/N105-, B7/N257-, A2/S269-, and A24/S1208-specific CD8
+ T cells were
pandemic PBMCs and tonsils by tetramer magnetic enrichment. Representative F
S1208-specific CD8
+ T cells from (A) acute and convalescent COVID-19 donors and
pandemic A2/S269 donors from Habel et al. [2020].
(C) B7/N105-specific CD8
+ T cell precursor frequencies were calculated for matche
Wilcoxin test.
(D) CD8+ precursor frequencies were calculated for B7/N105-, B7/N257-, A2/S269-
represent individual donors; data are shown as mean. Donors with undetectable p
tested; these donors were not included in statistical analyses. Statistical signific
otherwise.
See also Figure S4.N105-specific CD8+ T cells are present in high precursor
frequencies in pre-pandemic adult PBMCs and increase by
14.82-fold during SARS-CoV-2 infection in the peripheral blood.
SARS-CoV-2 tetramer-positive CD8+ T cells in pre-
pandemic individuals show predominantly naive
phenotype
The activation profiles of B7/N105-specific CD8+ T cells tested by
tetramer staining directly ex vivo from COVID-19 patients
and pre-pandemic donors across different ages were assessed
by CD27, CD45RA, and CD95 staining to determine the preva-
lence of the naive (TNaive) (CD27+CD45RA+CD95), stem cell
memory (TSCM) (CD27+CD45RA+CD95+), central memory
(TCM)-like (CD27+CD45RA), effector memory (TEM)-like
(CD27CD45RA), and effector memory CD45RA (TEMRA)
(CD27CD45RA+) subsets (Figure 3). As expected, COVID-19
donors displayed the lowest proportion of TNaive B7/N105+CD8+
T cells (mean of 10%) and instead had the highest proportion
of TCM-like B7/N105+CD8+ T cells (mean of 61%). Conversely,
pre-pandemic children and adult B7/N105+CD8+ T cells were
predominantly of the TNaive phenotype (p < 0.0001 for both age
groups in comparison with COVID-19 samples) and had minimal
activation profiles across all the T cell subsets tested (Figure 3C),
indicating that these B7/N105+CD8+ T cells constitute a naive
precursor pool rather than a pre-existing memory population
from exposure to other coronaviruses or pathogens. Although
cross-reactive memory T cell responses between human coro-
naviruses and SARS-CoV-2 have been described after stimula-
tion of pre-pandemic PBMCs with peptide megapools and
readouts by IFN-g production, these T cells usually express
distinct memory markers (Le Bert et al., 2020; Peng et al.,
2006), indicating that SARS-CoV-2 tetramer-reactive T cells
in our pre-pandemic samples are truly naive. Both
TNaive and TCM-like subsets varied across different elderly indi-
viduals, suggesting that B7/N105+CD8+ T cells in some elderly
individuals were either previously activated by cross-reactive
peptides or underwent age-related dysregulated homeostatic
proliferation, as commonly observed with age (LeMaoult et al.,
2000; Messaoudi et al., 2006; Valkenburg et al., 2012).
Naive profiles in pre-pandemic subdominant B7/N257-, A2/
S269-, and A24/S1208-specific CD8+ T cells largely reflected
those found for the immunodominant pre-pandemic B7/N105-
specific CD8+ T cells (Figure 3C). In COVID-19 patients, activa-
tion profiles of subdominant B7/N257-specific CD8+ T cells
were similar to those in immunodominant B7/N105-specific
CD8+ T cells and consisted largely of TCM phenotypes. Inific CD8+ but not subdominant B7/N257-, A2/S269-, and A24/S1208-spe-
identified directly ex vivo from COVID-19 PBMCs, as well as from healthy pre-
ACS plots of enriched and unenriched B7/N105-, B7/N257-, A2/S269-, and A24/
(B) pre-pandemic children (PBMCs and tonsils), adult, and elderly donors. Pre-
d children’s PBMC and tonsil samples, with statistical significance analyzed by
, and A24/S1208-specific CD8
+ T cells enriched from PBMCs and tonsils. Dots
recursor frequencies are included on the graph to show the number of donors
ance was determined with Dunn’s multiple comparison test unless indicated
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T cells in COVID-19 were more skewed toward TNaive, TSCM,
and/or TEMRA phenotypes.
Frequencies and phenotypes of SARS-CoV-2-specific
B7/N105+CD8+ T cells remain largely stable in
convalescent COVID-19 individuals
To assess whether the high numbers and TCM phenotype of B7/
N105-specific CD8+ T cells changed or remained stable over
time, we longitudinally sampled HLA-B*07:02-expressing
COVID-19 individuals from acute to convalescent time points
for up to 270 days post-disease onset (n = 9 COVID-19 patients,
22 samples). The longitudinal frequencies of B7/N105-specific
CD8+ T cells remained stable and relatively high, whereas the
very low numbers of subdominant B7/N257-specific CD8+ T fre-
quencies, many below the detection limit (<10 tetramer-positive-
enriched events), did not expand over time (Figures 4A and 4C).
Individual phenotypes were then tracked over time and across
age (Figures 4B and 4C), which generally showed very stable
populations of TCM-like B7/N105-specific CD8+ T cells in most
COVID-19 individuals, as well as in 1 individual with longitudinal
B7/N257-specific CD8+ T cell responses (Figure 4B). However,
TEMRA-like populations increased over time in 4 individuals
(CA6, 10, 11, and 13), 3 out of 4 being elderly donors (65 years
and over), whereas TSCM populations either increased or
decreased in certain individuals. Overall, apart from some fluctu-
ations in TSCM- and TEMRA-like populations, both the frequencies
and TCM-like phenotypes remained stable over time in convales-
cent individuals up to 270 days post-disease onset.
CD8+ T cells specific for B7/N105 display diverse TCRab
repertoire and promiscuous TCRa-TCRb pairing
The nature of the TCR repertoire can affect CD8+ T cell immuno-
dominance, functionality, and protection (Messaoudi et al.,
2002; Ndhlovu et al., 2015; Price et al., 2009). We therefore
defined the molecular signatures underpinning the immunodo-
minant B7/N105+CD8+ T cell response. We dissected TCRab
clonal composition and diversity with direct ex vivo tetramer
staining and human single-cell TCRab multiplex RT-PCR, as
described previously (Nguyen et al., 2017a; Valkenburg et al.,
2016). Here, we showed ex vivo dissection of TCRab repertoires
for immunodominant B7/N105-specific CD8+ T cells in PBMCs
from 4 HLA-B*07:02-expressing COVID-19 patients and 4 pre-
pandemic PBMC samples. We examined a total of 264 B7/
N105-specific CD8+ T cells TCRab pairs in total (Figure 5; Ta-
ble S2).
TCRab sequences were first analyzed for the overall TCRab
diversity on a per-individual basis (Figure 5A). Segments shownFigure 3. Ex vivo activation profiles of SARS-CoV-2-specific CD8+ T ce
(A and B) Representative FACS plots of B7/N105-, B7/N257-, A2/S269-, and A24/S12
(B) pre-pandemic children (PBMCs and tonsils), adult, and elderly donors sho
(CD27+CD45RA), TEM-like (CD27
CD45RA), and TEMRA (CD27
CD45RA+) sub
variations in flow cytometry settings (e.g., laser power, compensation, calibration),
for each individual before applying the gates to the smaller tetramer+ population.
were acquired on the same day.
(C) Stacked plots display the proportion of each phenotype subset within the B7
above the detection limit (R10 tetramer-positive-enriched events) were included f
with Tukey’s multiple comparisons test.by the same color represent TCRab clonotypes with the same V
segment usage but different CDR3 sequences. The B7/N105-
specific CD8+ TCRab repertoire of each COVID-19 patient was
generally diverse, with the presence of 1 to 3 largely expanded
TCRab clonotypes and a number (mean of 19 per donor) of
smaller TCRab clonotypes. Clone B (TRBV6-6/TRAV17) was de-
tected in 2 COVID-19 patients (Figures 5A and 5E), thus repre-
senting a shared TCRab clonotype for the B7/N105+CD8+ reper-
toire. Apart from cloneB, each donor had distinct usage of TRAV,
TRBV, TRAJ, and TRBJ gene segments, with no common gene
features found across the COVID-19 patients and no common
motifs within CDR3a and CDR3b sequences (Figure 5E; Table
S2). Similarly, the pre-pandemic B7/N105-specific CD8+ reper-
toires were highly diverse between donors, with no predominant
TCRab V-J gene sharing between them (Figure 5B).
Lack of common TCRab segment features was even more
evident whenwe analyzed the TCRab repertoire on a per-individ-
ual basis with circos plots (Figure 5C), with the color of the
segment indicating TRBV gene usage (on the left), and the pair-
ing with a specific TRAV segment depicted by the color of the
outer arch (on the right). Again, our circos analysis revealed a
remarkable level of diversity in TRAV and TRBV usage within
the individual COVID-19 patients and across the donors for
both COVID-19 and pre-pandemic, suggesting the plasticity of
TCRa-TCRb pairings. Across all COVID-19 and pre-pandemic
TCRs, only 1 COVID-19 patient (CA4, 2 clonotypes) shared the
same TRAV-TRBV pairing (TRBV29-1/TRAV13-1) with 1 pre-
pandemic individual (PP24, 8 clonotypes), with very similar
CDR3ab regions (Figure 5E). To further investigate TCRa-TCRb
pairings, we represented TRAV versus TRBV gene usage in a
bubble plot for COVID-19 patients. We found 26 different TRBVs
capable of pairing across 31 distinct TRAVs gene segments (Fig-
ure 5D). This shows that the TCRab diversity in B7/N105-specific
CD8+ T cells arises from distinct TCRab gene segment usage
and TRAV-TRBV pairings both across and within the donors
and not from being associated with any CDR3a or CDR3bmotifs
across different donors. These data suggest that promiscuity in
TCRa-TCRb pairing and CDR3a-CDR3b sequences (rather than
stringent requirements for TCRab common features) underlie
high naive precursor frequency within immunodominant B7/
N105-specific CD8+ T cells, capable of expansion after SARS-
CoV-2 infection.
A2/S269+CD8+ TCRab repertoire contains common
TRAV/TRAJ motifs
Because CD8+ T cells directed at SARS-CoV-2-specific A2/
S269 represent subdominant and suboptimal T cell specificity
in COVID-19 (Habel et al., 2020), we also investigated ex vivolls in COVID-19 and pre-pandemic donors
08-specific CD8




sets. To account for donor variability in the phenotype markers and day-to-day
phenotype gateswere first selected on the larger parent CD8+ T cell population
The same gates were used across time points from the same individual if they
/N105-, B7/N257-, A2/S269-, and A24/S1208-specific CD8
+ T cells. Only donors
or analysis; meanwith SD is shown, and statistical significancewas determined
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how it differs to that of immunodominant B7/N105-specific
CD8+ T cells. As we and others previously reported (Habel
et al., 2020; Peng et al., 2020), A2/S269-specific CD8+ T cells
detected ex vivo with tetramers represented a small but distinct
population in COVID-19 patients (n = 5; Figure 3A). The TCRab
repertoire displayed a considerable level of diversity by both
circos and bubble plots (Figures 6A–6C), although common
TRBV (43% of total 175 TCRs: TRBV2 at 11%, TRBV7-9 at
13%, TRBV20-1 at 20%), TRBJ (68% of total TCRs: TRBJ2-2
at 59%, TRBJ2-7 at 9%), TRAV (32% of total TCRs:
TRAV12-1 at 23%, TRAV12-2 at 3%, TRAV14/DV4 at 6%),
and TRAJ (24% of total TCRs: TRAJ43 at 18%, TRAJ30 at
6%) gene segments were found across different COVID-19 pa-
tients (Figures 6A and 6B; Table S3). More importantly, 2 key
TCRa motifs within the CDR3a loop were found across the
COVID-19 patients (Figure 6D). These included (1) TRAV12-1/
TRAJ43 CVVNXXXDMRF motif (where X denotes any amino)
found across all COVID-19 patients (16% of total TCR reper-
toire), paired with different prominent TRBV segments, and (2)
TRAV12-2/TRAJ30 CAVNXDDKIIF pairing with TRBV7-9
across 4 donors (except CA6) (3.4% of TCR repertoire), as
also recently reported by Shomuradova and colleagues (Sho-
muradova et al., 2020). These findings suggest that, in contrast
to the B7/N105-specific CD8+ repertoire with no common motif
and lack of shared TRBV, TRBJ, TRAV, or TRAJ gene segment
usage, TCRab clonotypes within the subdominant A2/S269-spe-
cific CD8+ T cells had dominant TRBV, TRBJ, TRAV, or TRAJ
gene segment usage across the donors and well-defined
CDR3a motifs, suggesting more rigid requirements for TCRab
clones capable of recognizing A2/S269 epitopes. Such lack of
TCRab plasticity most likely results in such low naive precursor
frequency (Habel et al., 2020).
CD8+ T cells specific for B7/N105 display high TCR
diversity within pre-pandemic PBMCs
To determine the extent of TCR diversity between pre-pandemic
B7/N105, COVID-19 B7/N105, and A2/S269 TCR repertoires, an in-
dependent analysis was performed with the TCRdist framework
(Dash et al., 2017) across equivalent numbers of TCRab pairs per
group to calculate diversity scores for single alpha and beta
chains and paired TCRab clonotypes (Figure 7A; Table S4). As
observed in our earlier analyses, the A2/S269 TCR repertoire
(paired TCRdiv = 147.9) was less diverse than both pre-
pandemic and COVID-19 B7/N105 repertoires, in which diversity
was mainly driven by the beta chain. Pre-pandemic B7/N105-
specific TCRs were extremely diverse (paired TCRdiv = 730.4)
and then narrowed after primary COVID-19 infection with
different individuals (paired TCRdiv = 299.9), although the latter
were still considered highly diverse. To contextualize the
COVID-19 TCR diversity with other well-established acute (influ-
enza A) and chronic viral infections (EBV and human cytomega-
lovirus [CMV]), the TCR diversity against the B7/N105 epitope
was reminiscent of the relatively diverse TCR repertoires againstFigure 4. Tracking longitudinal COVID-19 B7/CD8+ T cell responses up
(A) TAME-enriched precursor frequencies of B7/N105-specific CD8
+ and B7/N257
(B) Stacked bar graphs of each individual phenotype profiles of each donor acro
(C) Representative FACS plots of donors’ longitudinal B7/N105-specific CD8
+ T cethe chronic and immunodominant A2/CMV-pp65495-503 epitope.
Independent analysis of the commonCDR3motifs was also con-
ducted with TCRdist (Dash et al., 2017) to generate highly signif-
icant alpha and beta amino acid motifs for A2/S269 and B7/N105
TCRs (Figure 7B; Figure S5). Similar to our initial analysis
(Figure 6D), COVID-19 A2/S269 TCR repertoire generated 2
dominant alpha motifs (TRAV12-2/12-1-TRAJ43/30), where the
gene pairing of TRAV12-1 with TRAJ43 was highly significant
(p < 2.3E07, Figure S6). In comparison, COVID-19 B7/N105
TCR repertoire encompassed several alpha and beta chain mo-
tifs which, surprisingly, did not overlap with the pre-pandemic
B7/N105 motifs.
The probability of generating (Pgen) TCR alpha and beta chains
were then calculated with TCRdist, which correlated with the
number of insertions and deletions within the CDR3 region (Fig-
ure 7C). Within the TCR alpha chain, Pgen values were similar for
COVID-19 and well-established IAV, EBV, and CMV epitopes.
The probability of generating beta chains in the B7/N105 groups
was comparable between pre-pandemic and COVID-19, but
both COVID-19 and pre-pandemic B7/N105’s Pgen were signifi-
cantly lower than those of A2/S269 (padj = 0.0012 and 0.0435,
respectively) but similar to the A2/CMV repertoire. The lower
beta Pgen values for B7/N105 were supported by both B7/N105
groups having significantly more beta N-insertions than A2/
S269; however, lower numbers of N deletions were only signifi-
cantly observed for the COVID-19 B7/N105 TCR repertoire, but
not for pre-pandemic B7/N105 or A2/S269. Taken together, the
lower probability of generating B7/N105 TCRs, by way of more in-
sertions, reflects the extreme nature in diversity for both pre-
pandemic and COVID-19 B7/N105 TCR repertoires.
DISCUSSION
Our study deciphered the most immunodominant CD8+ T cell
response known to date in COVID-19, the B7/N105+CD8+ T cell
population. Our direct ex vivo approach, without any in vitroma-
nipulations, revealed high precursor frequencies of B7/N105-spe-
cific CD8+ T cells in COVID-19 patients (6.88 3 104), compa-
rable to the magnitude of a well-established influenza-specific
A2/M158-specific CD8+ T cell memory population (3.04 3
104). High precursor frequencies were also detected in pre-
pandemic adult and elderly PBMCs (3.00 3 105 and 6.76 3
105, respectively), much higher than the precursor frequencies
previously observed for naive CD8+ T cells directed toward HLA-
A*02:01-restricted NY-ESO-11157-1165, WT1126-134, HIV Gag
p1777-85, HCV Core132-140, and CMV pp65 antigens (between
0.6 3 106 to 5.3 3 106) in cancer-free and seronegative indi-
viduals (Alanio et al., 2010; Nguyen et al., 2017b). It was thus
quite surprising that these B7/N105-specific CD8+ T cells in
pre-pandemic samples mainly displayed a naive phenotype,
indicating a lack of previous cross-reactive exposures. Because
the SARS-CoV-2-derived N105-113 peptide SPRWYFYYL dis-
plays a close amino acid (aa) homology with the corresponding
peptide LPRWYFYYL derived from N in the globally distributedto day 270 post disease onset
-specific CD8+ T cells from each individual with multiple time points.
ss age.
ll responses in terms of TAME-enriched (i) tetramer and (ii) phenotype profiles.
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Figure 5. Diverse TCRab repertoire and promiscuous TCRa-TCRb pairing within B7/N105-specific CD8
+ T cells
(A and B) B7/N105-specific CD8
+ T cells were enriched by TAME and then single-cell sorted for TCRab analysis. Pie charts of TRBV and TRAV gene usage in B7/
N105
+CD8+ T cells in (A) COVID-19 (n = 4) and (B) pre-pandemic donors (n = 4). All COVID-19 patients were from convalescent samples with one exception, where
(legend continued on next page)
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Articlecoronavirus strains HCoV-OC43 and HCoV-HKU1, there is po-
tential for cross-reactive CD8+ T cell responses, which was
notably observed in all 4 donors tested by Ferretti et al.’s study
via genome-wide epitope screening technology and the secre-
tion of granzyme B (Ferretti et al., 2020; Schulien et al., 2021).
However, the overall conclusion was that the COVID-19 CD8+
T cell response was not significantly shaped by pre-existing im-
munity to endemic coronaviruses. However, because 100% of
the pediatric and 81.3% of adult pre-pandemic donors in our
study had a prototypical naive (and not even TSCM) B7/N105-spe-
cific CD8+ T cell phenotype directly ex vivo, this suggests that
either the HCoV-OC43/HKU1 peptide is not presented on the
infected cell surface (for example due to different processing
of the peptide within the cell), the SARS-CoV-2-derived
N105–113 peptide is not cross-reactive with the corresponding
N-derived peptides originating from other human coronaviruses,
or our pre-pandemic adult and pediatric donors were not
exposed to those circulating coronaviruses. Although we cannot
exclude that these CD8+ T cells are naive antigen-experienced
T cells that express a naive CD45RA+CD27CD95 phenotype,
our previous study indicated that the SARS-CoV2 A2/S269-spe-
cific CD8+ T cells with naive CD45RA+CD27+CD95 phenotype
could not respond to the peptide stimulation (Habel et al.,
2020). These data are in line with previous phenotypical analysis
of human coronavirus-specific T cells which do not express a
naive phenotype (Le Bert et al., 2020; Peng et al., 2006), indi-
cating that infection with human coronaviruses might not induce
SARS-CoV-2 B7/N105–113-specific T cells. We have not found
effector and/or memory SARS-CoV-2 tetramer-positive CD8+
T cells in lungs or spleens from pre-pandemic donors, in contrast
to readily detected memory influenza tetramer-positive CD8+
T cells across different epitopes found at these anatomical sites
in our previous studies (Koutsakos et al., 2019; Sant et al., 2018).
Both the magnitude and phenotype of B7/N105-specific CD8+
T cells were highly variable in the pre-pandemic elderly.
Reduced magnitude of B7/N105-specific CD8+ T cells in elderly
individuals corresponds with published reports providing clear
evidence for a loss of tetramer-positive CD8+ T cells as well as
naive CD8+ T cell precursors with aging (Nguyen et al., 2018; Val-
kenburg et al., 2012). Although B7/N105-specific CD8+ T cells
within 4 elderly donors mainly had a naive phenotype, 3 donors
had a high prevalence of TEMRA (75%) and TCM-like (37%–
73%) subsets. This could be due to either priming with cross-
reactive peptides derived from circulating coronaviruses
occurring sequentially with age or SARS-CoV-2 CD8+ T cells un-
dergoing age-related dysregulated homeostatic proliferation, as
commonly observed with age and CMV seropositivity (LeMaoult
et al., 2000; Messaoudi et al., 2006; Valkenburg et al., 2012;Wer-
theimer et al., 2014). The high frequency of TEMRA-phenotype
T cells observed in PP27 could be a result of age-related
CD45RA upregulation observed previously in CMV-specific
CD8+ T cells (Griffiths et al., 2013). It is, however, unclear whether5 out of 36 TCR clonotypes for Donor CA12 were from the acute time point. Seg
segment usage but different CDR3 sequences.
(C) Circos plots of TRBV and TRAV clonotype pairings; left arch and segment co
(D) Bubble plot showing the distribution (number of donors and frequency) of TR
(E) Dominant clonotypes identified in HLA-B*07:02 donors specific to B7/N105
+C
See also Table S2.this upregulation also occurs in antigen-specific CD8+ T cells in
acute infection in contrast to constant exposure to antigens
derived from persistent infections such as CMV, given that
persistent infections can induce different memory phenotypes
(Appay et al., 2002).
Because our TCRab analysis of the B7/N105-specific CD8+
T cells obtained from the pre-pandemic elderly individual
(PP27) with the high-frequency TEMRA population showed a
highly clonal TCRab repertoire, atypical of what we observed
in other COVID-19 and pre-pandemic individuals, this sug-
gested that the clonal B7/N105-specific CD8+ TEMRA population
in this elderly individual represented a highly proliferating
non-COVID-19-specific CD8+ T cell population. Whether or
not the frequencies of SARS-CoV-2 tetramer-positive CD8+
T cells within adult tonsils are higher than those in adult blood
will require future investigation. From our previous study, we
found higher levels of influenza-specific CD8+ T cells in healthy
adult tonsils than in unmatched healthy adult blood (Koutsakos
et al., 2019).
Our analyses of longitudinal COVID-19 samples for B7/
N105+CD8+ T cell populations demonstrated the maintenance
of predominant TCM-like phenotypes into the long-term mem-
ory (up to d270 for some patients) after disease onset, similar
to what we observed in patients hospitalized with H7N9 in
Shanghai (Wang et al., 2015). Our findings are in agreement
with studies showing that SARS-CoV-specific memory T cells
persist into long-term memory for at least 6 to 11 years (Peng
et al., 2006; Tang et al., 2011). However, it should be noted
that distinct memory populations can be established after
infection with different viruses (Appay et al., 2002) or
even across different epitope-specific CD8+ T cells, as exem-
plified by our recent study (Habel et al., 2020) showing mainly
TSCM/naive phenotypes within A2/S269+CD8+ T cells during
convalescence.
Ex vivo TCRab analyses for the remaining COVID-19 patients
and pre-pandemic samples across all ages revealed that a
diverse TCRab repertoire and promiscuity in TCRa-TCRb pairing
could underlie such high naive precursor frequencies of B7/N105-
specific CD8+ T cells. The importance of TCRab repertoire diver-
sity on disease outcome was previously reported (LeMaoult
et al., 2000) in mice, macaques, and humans (Messaoudi et al.,
2002; Chen et al., 2012; Price et al., 2009). Generally, a diverse
TCRab repertoire provides a greater scope for selection of
TCRab clonotypes with high peptide-MHC-I avidity. CD8+
T cells with diverse TCR repertoires can generate broadly pro-
tective responses and are often capable of recognizing both
the wild-type virus and newly emerging mutants. Our single-
cell ex vivo TCRab analysis, including independent analysis
with the TCRdist framework, demonstrated higher TCRab diver-
sity within immunodominant B7/N105-specific CD8+ T cells with
variable usage of TRAV, TRBV, TRAJ, and TRBJ gene segments.
Furthermore, no common gene features and no common motifsments shown by the same color represent TCRab clonotypes with the same V
lor indicate TRBV usage, and right outer arch color depicts TRAV usage.
BV/TRAV gene usage in COVID-19 patients.
D8+ T cells. ND, not determined.
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Figure 6. Common TRAV/TRAJ motifs within suboptimal A2/S269-specific CD8
+ TCRab repertoire
A2/S269
+CD8+ T cells from COVID-19 PBMCs were identified ex vivo and enriched by TAME before single-cell sorting for TCRab analysis.
(A) Pie charts of TRBV and TRAV gene usage in A2/S269
+CD8+ T cells in acute and convalescent COVID-19 donors. Segments shown by the same color represent
TCRab clonotypes with the same V segment usage but different CDR3 sequences.
(B) Circos plots of TRBV and TRAV clonotype pairings; left arch and segment color indicates TRBV usage, and right outer arch color depicts TRAV usage. Ac,
acute; Fup, follow-up convalescent sample.
(C) Bubble plot showing the distribution (number of donors and frequency) of TRBV/TRAV gene usage.
(D) Dominant clonotypes identified in HLA-A*02:01 donors specific to A2/S269
+CD8+ T cells. X denotes any amino acid, and (n) denotes any number of additional
amino acids.
See also Table S3.
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Articlewithin CDR3a and CDR3b sequences were observed across the
donors. Such TCRab repertoire diversity, combinedwith the pro-
miscuity of TCRa-TCRb pairing, might reflect a high degree of1078 Immunity 54, 1066–1082, May 11, 2021TCRab plasticity to recognize the immunodominant B7/N105
epitope. Consequently, this plasticity could lead to the genera-
tion of a large and diverse pool of naive TCRab precursors
(legend on next page)
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T cells. When it comes to immunodominance hierarchies, both
naive precursor frequency and antigen dose play a key role (La
Gruta et al., 2006). Thus, a high naive precursor frequency in
pre-pandemic samples could underlie highly immunodominant
B7/N105+CD8+ T cell responses in COVID-19 patients during
acute disease and convalescence. Future crystallography
studies of ternary N105 peptide in the context of HLA-B*07:02
and TCRabs are needed to provide key insights into promiscu-
ous TCRab recognition of the B7/N105 epitope, as well as the in-
clusion of more nucleocapsid-derived epitopes and tetramers
for further TCR repertoire studies. The TCRab repertoire within
the dominant B7/N105-specific CD8+ T cells contrasted those
of subdominant SARS-CoV-2-specific A2/S269-specific CD8+
T cells containing clear CDR3a motifs and TRAV usage (as
shown by our study and the recent report by Shomuradova
et al., [2020]). The latter reflected numerous previously analyzed
TCRab repertoires of viral-specific CD8+ T cell populations in
mice and humans, characterized by biased usage of TCR gene
segments (Kedzierska and Koutsakos, 2020).
Overall, our study suggests that high precursor frequency and
plasticity of TCRa-TCRb pairing underpin the immunodomi-
nance of SARS-CoV-2-specific B7/N105+CD8+ T cell responses.
As both the immunodominant B7/N105 and subdominant B7/
N257 SARS-CoV-2-specific epitopes encompass nucleocapsid-
derived peptides, infection with SARS-CoV-2 clearly leads to
robust CD8+ T cell immunity in HLA-B*07:02 individuals. Better
understanding of T cells directed toward immunodominant epi-
topes and their origins provides important insights into the
rational design of next-generation vaccine strategies to optimize
long-lasting CD8+ T cell immunity.
Limitations of the study
We recognize that our pre-pandemic andCOVID-19 donors orig-
inate from 1 country and thus do not represent the global popu-
lation. This might be especially relevant when CD8+ T cell re-
sponses toward the circulating human coronavirus strains are
assessed. Cross-reactivity of CD8+ T cell responses against
different SARS-CoV-2 variants was not addressed in the current
manuscript and is of interest for future studies. The number of
pre-pandemic children’s samples was relatively small to perform
in-depth analyses. Further ex vivo examination of tetramer-pos-
itive CD8+ T cells in SARS-CoV-2-infected children would be of a
great interest to understand SARS-CoV-2-specific CD8+ T cells
responses in acute COVID-19 and convalescence.Figure 7. TCR repertoire diversity and distinct single-chain motifs with
(A) Single alpha, beta, and paired TCRdiv diversity values between COVID-19 A2
(43 out of 75) and B7/N105 TCRs (42 out of 82) were randomly down-sampled to
group. The higher value indicates higher diversity.
(B) Enriched alpha and beta amino acid motifs in the CDR3 region were generate
side) and joining (right side) gene frequencies, CDR3 amino acid sequences (m
region: light gray, V-region; dark gray, J-region; black, diversity [D]-region; red, ins
values below 50 were borderline significant. The full set of motifs are shown in F
(C) Probabilities of generation (Pgen; log10 transformed), and number of nucleotid
with the TCRdist pipeline and contextualized with publicly available data from A
repertoires, which were not included in the statistical analysis. Statistical analys
ertoires for variations in Pgen, insertions, and deletions are further described in t
multiple testings with the Benjamini and Hochberg FDR method. Box plots repr
(lower hinge), with whiskers extending 1.5 times the inter-quartile range.
See also Table S4, Figure S5, and Figure S6.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
A total of 21 COVID-19 cases (CA) and 40 pre-pandemic (PP) subjects were recruited into this study (Table S1). The traveler cohort
included 3 COVID-19 cases (CA1-3) at convalescence and 4 suspected cases (SU1-4). Acute and convalescent COVID-19 patients
were recruited via the Alfred Hospital, Austin Hospital, University of Melbourne or James Cook University. Eight of the donors were
admitted to hospital during their active infection (Table S1). Healthy pre-pandemic blood donors were recruited via the University of
Melbourne or buffy packs obtained from the Australian Red Cross LifeBlood (West Melbourne, Australia) (Table S1). Healthy COVID-
19-unexposed and pre-pandemic tonsils, spleens and lungs were also obtained. Matched tonsils and PBMCs were obtained from
healthy individuals undergoing tonsillectomy (LauncestonGeneral Hospital, Tasmania, Australia), lung samples via the Alfred Hospital’s
Lung Tissue Biobank, while spleens were provided by DonateLife Victoria. Donors were HLA typed by VTIS (Melbourne, Australia). Pe-
ripheral blood was collected in heparinized tubes and peripheral blood monocular cells (PBMCs) were isolated via Ficoll-Paque sepa-
ration. Single cell suspensions were isolated from tissues as previously described (Habel et al., 2020; Koutsakos et al., 2018).
Experiments conformed to the Declaration of Helsinki Principles and the Australian National Health and Medical Research Council
Code of Practice. Written informed consents were obtained from all blood donors prior to the study. Lung and spleen tissues were
obtained from deceased organ donors after written informed consents from the next of kin. Written informed consents were obtained
from participants’ parental or guardians for underage tonsil tissue donors. The study was approved by the Alfred Hospital (#280/14),
Austin Health (HREC/63201/Austin-2020); the University of Melbourne (#2057366.1, #2056901.1, #2056689, #2056761, #1442952,
#1955465, and #1443389), the Australian RedCross Lifeblood (ID 2015#8), the Tasmanian Health andMedical (ID H0017479) and the
James Cook University (H7886) Human Research Ethics Committees.
METHOD DETAILS
Peptides and peptide-HLA class I tetramers
Overlapping synthetic peptides spanning the SARS-CoV-2 Nucleocapsid (N) and Membrane (M) proteins, and the immunogenic
regions of Spike (S) were purchased from Miltenyi Biotec and reconstituted in 80% DMSO. SARS-CoV-2 peptides shown to bindImmunity 54, 1066–1082.e1–e5, May 11, 2021 e3
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N219-227 LALLLLDRL; A2/N222-230 LLLDRLNQL and A24/S1208 QYIKWPWYI) were purchased from GenScript and reconstituted in
DMSO. Tetramers were generated from soluble, biotinylated HLA-B*07:02 or HLA-A*24:02 monomers. Briefly, HLA a-heavy chain
with C-terminal BirA biotinylation motif and b2-microglobulin were expressed and purified as inclusion bodies in E. coli, solubilized
in 6MGuanidine HCl and refolded with either N105, N257, N66 (for HLA-B*07:02) or S1208 (for HLA-A*24:02) peptide, in buffer containing
50mM Tris pH8, 3M urea, 0.4M Arginine, 2mM oxidised Glutathione, 20mM Glutathione, 2mM EDTA, 10mM PMSF and cOmplete
protease inhibitor (Roche). Following dialysis in 10mM Tris, HLA monomers were purified via DEAE and HiTrapQ ion exchange chro-
matography, and biotinylated with BirA ligase in 50mM Bicine pH 8.3, 10mM ATP, 10mM magnesium acetate and 100mm d-biotin.
Following S200 gel permeation chromatography fully biotinylated HLA monomers were stored at 80C and conjugated to fluores-
cently-labeled streptavidin (SA), PE-SA or APC-SA (BD Biosciences) at an 8:1 monomer to SAmolar ratio to form pMHC-I tetramers.
The A2/S269 (SARS-CoV-2, S269, YLQPRTFLL) and B7/EBV (EBNA-3379-387, RPPIFIRRL) tetramers were generated as previously
described (Habel et al., 2020) (Rowntree et al., 2020).
Ex vivo tetramer enrichment
PBMCs, tonsils and spleens (7-50x106) were stained with B7/N105-PE, B7/N257-APC, A2/S269-PE or A24/S1208-APC tetramers at
room temperature for 1 h in MACS buffer (PBS with 0.5% BSA and 2 mM EDTA). Cells were then incubated with anti-PE and
anti-APC microbeads (Miltenyi) and tetramer+ cells were enriched using magnetic separation (Nguyen et al., 2017b; Valkenburg
et al., 2016). Lymphocytes were stained with anti-CD71-BV421 (#562995), anti-CD4-BV650 (#563875), anti-CD27-BV711
(#563167), anti-CD38-BV786 (#563964), anti-CCR7-AF700 (#561143), anti-CD14-APC-H7 (#560180), anti-CD19-APC-H7
(#560177), anti-CD45RA-FITC (#555488), anti-CD8-PerCP-Cy5.5 (#565310), anti-CD95-PE-CF594 (#562395), anti-PD1-PE-Cy7
(#561272) (BD Biosciences), anti-CD3-BV510 (#317332), anti-HLA-DR-BV605 (#307640) (BioLegend, San Diego, CA, USA) and
Live/Dead near-infrared (#L10119, Invitrogen) stain for 30 min, washed, resuspended in MACS buffer and analyzed by flow cytom-
etry. Lung cells were stained with tetramer for 1 h then cell surface stained using a modified panel to include anti-CD69-BV421
(#310930), anti-CD103-FITC (#350203) (BioLegend) and anti-CD45RO-PE-Cy7 (#25-0457-41, Thermo Fisher Scientific). In some ex-
periments, cells were fixed with 1% PFA and washed before acquiring on a LSRII Fortessa (BD) or single cell sorted using the
FACSAriaIII (BD) for TCR analyses. FCS files were analyzed using FlowJo v10 software.
TCRab repertoire analysis
Tetramer+ CD8+ T cells were single-cell sorted into empty 96-well Twin.tec PCR plates (Eppendorf, Hamburg, Germany), centrifuged
then stored at 80C. Multiplex-nested RT-PCR amplification of paired CDR3a and CDR3b regions were performed as described
(Nguyen et al., 2017b; Valkenburg et al., 2016). TCR sequences were analyzed using IMGT/V-QUEST. Data visualization was per-
formed in R using packages for circular layout (Gu et al., 2014) and graphics generation (Wickham, 2016).
Phenotypic whole blood immune analyses
Fresh whole blood was used to analyze immune cell populations using three human antibody panels for enumerating immune cell
activation (monocytes and T/B/NK/gd cells), TFH and ASC cell activation, and cytotoxicity profiles of T cell’s expressing intracellular
granzymes (A, B, K andM) and perforin, as previously described (Thevarajan et al., 2020). PBMCs were stained, red blood cell lysed,
then fixed in 1% PFA, or intracellularly stained using the eBioscienceTM Foxp3/Transcription Factor Staining Buffer Set (Thermo
Fisher Scientific, Carlsbad, CA, USA) (Thevarajan et al., 2020). Samples were acquired on a BD LSRII Fortessa and analyzed using
FlowJo v10 software.
Detection of SARS-CoV-2 RBD- and Spike-reactive B cells
PBMCs were stained with SARS-CoV-2 Spike and RBD probes, as previously described (Juno et al., 2020). Probes were generated
by sequential addition of streptavidin-phycoerythrin (PE) (Thermo Fisher Scientific) to trimeric S protein biotinylated using recombi-
nant Bir-A (Avidity), while SARS-CoV-2 RBDwas labeled to APC using an APCConjugation Lightning-Link Kit (Abcam). PBMCswere
surface stained with Aqua viability dye (Thermo Fisher) and monoclonal antibodies against CD19-ECD (#IM2708U, Beckman
Coulter), IgM BUV395 (#563903), CD21 BUV737 (#564437), IgD PE-Cy7 (#561314), IgG BV786 (#564230), streptavidin-BV510
(#563261) (BD Biosciences), CD20 APC-Cy7 (#302314), CD14 BV510 (#301841), CD3 BV510 (#317332), CD8a BV510 (#301048),
CD16 BV510 (#302048), CD10 BV510 (#312220) and CD27 BV605 (#302829) (BioLegend). Cells were washed, fixed with 1% form-
aldehyde and acquired on a BD LSRII Fortessa.
Intracellular cytokine staining (ICS)
PBMCswere stimulatedwith 0.6 nmol of overlapping SARS-CoV-2 peptides for 10 days in RF-10medium (+10U/mL IL-2) (Koutsakos
et al., 2019). On d10, cells were stimulated with peptides for 5-6 h in the presence of GolgiPlug and GolgiStop (BD Biosciences) plus
10U/mL IL-2, and SARS-CoV-2-reactive T cells were quantified using anti-IFN-g-V450 (#560371), anti-TNF-AF700 (#557996), anti-
MIP-1b-APC (#560686) (BD Biosciences), and anti-CD107a-AF488 (#53-1079-42, Thermo Fisher Scientific) in an ICS assay as pre-
viously described (Clemens et al., 2016).e4 Immunity 54, 1066–1082.e1–e5, May 11, 2021
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RBD- and Spike-specific ELISA for detection of IgM, IgG and IgA antibodies was performed as described (Amanat et al., 2020; Stadl-
bauer et al., 2020), with some modifications: Nunc MaxiSorp flat bottom 96-well plates (Thermo Fisher Scientific) were used for an-
tigen coating, blocking with PBS (containing w/v 1%BSA) and serial dilutions performed in PBS (containing v/v 0.05% Tween and w/
v 0.5% BSA). For detection of IgG and IgA, peroxidase-conjugated goat anti-human IgG (Fcg fragment specific; Jackson ImmunoR-
esearch) or alkaline phosphate-conjugated rat anti-human IgA (mAb MT20; MabTech) was used and developed with TMB (Sigma)
substrate for IgG or pNPP (Sigma) for IgA. For IgM, biotinylated mAbMT22 and peroxidase-conjugated streptavidin (Pierce; Thermo
Fisher Scientific) was used. Peroxidase reactions were stopped using 1M H3PO4 and plates read on a Multiskan plate reader (Lab-
systems). Inter- and intra-experimental measurements were normalized using a positive control plasma from a COVID-19 patient run
on each plate. Endpoint titers were determined by interpolation from a sigmodial curve fit (all R-squared values > 0.95; GraphPad
Prism 8) as the reciprocal dilution of plasma that produced > 15% (for IgA and IgG) or > 30% (for IgM) absorbance of the positive
control at a 1:31.6 (IgG and IgM) or 1:10 dilution (IgA). Seroconvertion was defined when titers were above the mean titer (plus 2 stan-
dard deviations) of healthy non-COVID-19 donors.
Microneutralisation assay
Microneutralisation activity of serum samples was assessed as previously described (Juno et al., 2020). SARS-CoV-2 isolate CoV/
Australia/VIC01/2020 (Caly et al., 2020) was propagated in Vero cells and stored at 80C. Sera were heat-inactivated at 56C for
30 min and serially diluted. Residual virus infectivity in the serum/virus mixtures was assessed in quadruplicate wells of Vero cells
incubated in serum-free media containing 1 mg/mL of TPCK trypsin at 37C and 5% CO2. Viral cytopathic effect was read on day
5. The neutralising antibody titer was calculated using the Reed–Muench method, as described (Juno et al., 2020).
Cytokine analysis
Patients’ plasma was diluted 1:2 for measuring IL-1b, IFN-a2, IFNg, TNFa, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-
17A, IL-18, IL-23 and IL-33 using the LEGENDplex Human Inflammation Panel 1 kit, as per manufacturer’s instructions (BioLegend).
QUANTIFICATION AND STATISTICAL ANALYSIS
TCR statistical analysis
Single-chain alpha and beta TCR sequences were independently parsed and analyzed using the TCRdist pipeline to detect statis-
tically significant amino acid motifs and tomodel CDR3 insertions, deletions, and probabilities of generation (Pgen) (Dash et al., 2017).
To test for variations in Pgen, insertions, and deletions across epitope specificities, we used linear mixed models (Bates et al., 2014)
with the number of sequences per subject per epitope included as a covariate and subject included as a random effect in order to
control for unintentional differences in sequencing effort and non-independence of the data across subjects, respectively. Log10 of
Pgen was modeled using a Gaussian distribution, whereas insertions and deletions were analyzed using a generalized model for the
negative binomial distribution. P valueswere adjusted (padj) formultiple testing using the Benjamini & Hochberg FDRmethod.We also
used the TCRdist framework on a subset of the data to characterize repertoire diversity using TCRdiv, which was contextualized us-
ing publicly available data from A2/EBV-BMLF1280-288, A2/M158-66 (influenza A), and A2/CMV-pp65495-503 repertoires. For this anal-
ysis, we only considered cells that had functional, paired alpha and beta sequences, and we randomly down-sampled repertoires
such that each were derived from an equivalent number of donors and had an equivalent number of TCRs for comparison (i.e.,
A2/S269, B7/N105 COVID-19, A2/EBV, A2/M1 and A2/CMV). The subsampled and full repertoires are detailed in Table S4.
Statistical analysis
Statistical significance of nonparametric datasets (two-tailed) were determined using GraphPad Prism v9 software. Mann-Whitney
(unpaired) and Wilcoxin (paired) tests were used for comparisons between two groups. Kruskal-Wallis (unmatched) test with Dunn’s
multiple comparisons was used to compare more than two groups. Tukey’s multiple comparison test compared rowmeans between
more than two groups.Immunity 54, 1066–1082.e1–e5, May 11, 2021 e5
